The $75M raise provides cash runway for clinical development but at a 21% discount to the prior close (assuming $4.00 vs. $5.07 pre-announcement). Monitor for potential further dilution if the underwriters' option is exercised. The stock may face continued pressure as the market absorbs the new shares. Watch for pipeline updates on SL-325 as the primary catalyst for future value.
Price Chart
Executive Summary
Shattuck Labs priced a public offering of 10,879,376 common shares at $4.00/share and pre-funded warrants for 7,870,624 shares at $3.9999/warrant, expecting ~$75M in gross proceeds. The offering closes June 11, 2026, with underwriters having a 30-day option for an additional 2,812,500 shares. This dilutive capital raise provides cash runway for a clinical-stage biotech with no approved products, signaling near-term financing needs.
Key Financial Metrics
Key Facts
- Offering of 10,879,376 common shares at $4.00/share and pre-funded warrants for 7,870,624 shares at $3.9999/warrant.
- Expected aggregate gross proceeds of approximately $75 million.
- Underwriters have a 30-day option to purchase up to an additional 2,812,500 shares.
- Offering expected to close on June 11, 2026.
- Pre-funded warrants have an exercise price of $0.0001 per share and are immediately exercisable.
- Shattuck Labs is a clinical-stage biotech with no approved products, focused on DR3 blocking antibodies for inflammatory diseases.
Financial Impact
Approximately $75 million gross proceeds from the offering, representing significant dilution to existing shareholders. Based on the $4.00 offering price and pre-offering market cap of ~$299M, the new shares (excluding the underwriters' option) represent roughly 18.7% dilution (10.88M new shares vs. ~74.75M pre-offering shares, estimated from market cap/price).
Risk Factors
- Dilution of approximately 18.7% from the offering (excluding underwriters' option), which could further increase if the option is exercised.
- Clinical-stage biotech with no approved products; reliance on successful development of SL-325.
- Potential for additional capital raises in the future given the cash-intensive nature of clinical trials.
- Underwriters' option for up to 2,812,500 additional shares could add further dilution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3309437 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 10w ago | 8-K | $7.18 $7.45 | ▲ +3.76% | ▲ +4.16% | $5.54 (−22.84%) |
Aug 11, 2026 11w ago | Press Release | $7.18 $7.45 | ▲ +3.76% | ▲ +4.16% | $5.54 (−22.84%) |
Jul 7, 2026 15w ago | Insider Cluster | $6.88 $6.29 | ▼ −8.58% | ▼ −9.44% | $5.54 (−19.48%) |
Jul 2, 2026 16w ago | Insider Cluster | $7.05 $7.03 | ▼ −0.28% | ▼ −1.21% | $5.54 (−21.42%) |
Jun 11, 2026 19w ago | 8-K | $4.18 $4.74 | ▼ −13.40% | ▼ −12.96% | $5.54 (−32.54%) |
Jun 11, 2026 19w ago | Institutional Cluster | $4.18 $4.74 | ▼ −13.40% | ▼ −12.96% | $5.54 (−32.54%) |
Jun 11, 2026 19w ago | 424B5 | $4.18 $4.74 | ▼ −13.40% | ▼ −12.96% | $5.54 (−32.54%) |
Jun 10, 2026 19w ago | Press Release | $4.13 $4.33 | ▼ −4.84% | ▼ −1.41% | $5.54 (−34.14%) |
Jun 9, 2026 19w ago | 424B5 | $4.13 $4.33 | ▼ −4.84% | ▼ −1.41% | $5.54 (−34.14%) |
Jun 9, 2026 19w ago | 8-K | $4.13 $4.33 | ▲ +4.84% | ▲ +1.41% | $5.54 (+34.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers